Arbutus Biopharma Corporation (ABUS)
ABUS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/0001447028-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ABUS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001447028 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | BC |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $14.1M |
| Net income | -$33.5M |
| Operating income | -$38.2M |
| Net margin | -237.9% |
| Operating margin | -271.0% |
| Revenue growth | +128.2% |
| Cash | $18.0M |
| Total assets | $94.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 44.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $264.2M cash; operating cash flow $55.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 153,292,826 (2026-11-06); 192,324,017 a year earlier; 167,695,247 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-04-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $299K | $59.1M | $239.8M | $264.2M | $0 | $181.5M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $1.0M | -$5.1M | -$6.0M | $19.2M | $0 | $181.7M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $179.1M | $169.7M | -$8.1M | $23.7M | $0 | $191.4M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $1.1M | -$3.8M | -$4.7M | $18.0M | $0 | $14.1M | 10-K 2026-03-23 |
| Q3 2025 2025-09-30 | $529K | -$7.7M | -$5.8M | $22.4M | $0 | $14.6M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $10.7M | $2.5M | -$15.7M | $37.4M | $0 | $15.4M | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $1.8M | -$24.5M | -$13.4M | $37.1M | $0 | $6.4M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $1.6M | -$12.5M | -$10.3M | $36.3M | $0 | $6.2M | 10-K 2026-03-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2024-11-06 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report FORM 8-K | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-14 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +11.7% |
| 1 month | -0.5% |
| 3 months | -10.7% |
| Year to date | -15.0% |
| 1 year | -10.3% |
| From 52-week high | -21.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMMX | Immix Biopharma Inc. | $7.48 | -4.59% | $626.9M |
| GERN | Geron Corporation | $0.9419 | -2.60% | $606.8M |
| DSGN | Design Therapeutics Inc. | $9.92 | -5.25% | $635.2M |
| AVBP | ArriVent BioPharma Inc. | $11.56 | -11.15% | $597.9M |
| OLMA | Olema Oncology Inc. | $7.36 | -2.65% | $644.8M |
| ANL | Adlai Nortye Group Ltd. | $10.03 | -5.47% | $645.9M |
| BCAX | Bicara Therapeutics Inc. | $9.75 | -2.69% | $647.3M |
| KURA | Kura Oncology Inc. | $7.09 | -8.75% | $651.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier